BPMX - BioPharmX Corporation

NYSE American - NYSE American Delayed Price. Currency in USD
0.1162
-0.0003 (-0.26%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.1165
Open0.1172
Bid0.0000 x 900
Ask0.1225 x 2200
Day's Range0.1150 - 0.1200
52 Week Range0.1000 - 0.3750
Volume1,966,542
Avg. Volume2,789,662
Market Cap24.729M
Beta (3Y Monthly)-2.03
PE Ratio (TTM)N/A
EPS (TTM)-0.1140
Earnings DateDec 5, 2018 - Dec 10, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.00
Trade prices are not sourced from all markets
  • PR Newswire9 days ago

    BioPharmX Reports Third Quarter 2019 Financial Results

    MENLO PARK, Calif. , Dec. 6, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today reports ...

  • Is BioPharmX Corporation’s (NYSEMKT:BPMX) Balance Sheet Strong Enough To Weather A Storm?
    Simply Wall St.11 days ago

    Is BioPharmX Corporation’s (NYSEMKT:BPMX) Balance Sheet Strong Enough To Weather A Storm?

    BioPharmX Corporation (NYSEMKT:BPMX), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is BPMX will Read More...

  • PR Newswirelast month

    BioPharmX Announces NYSE American Acceptance of Plan To Regain Listing Compliance

    MENLO PARK, Calif., Nov. 16, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX) (the "Company"), a specialty pharmaceutical company developing products for the dermatology market, announced that on November 1, 2018, NYSE Regulation accepted the Company's plan to regain compliance with the NYSE American LLC ("NYSE American") continued listing standards set forth in Sections 1003(a)(iii) of the NYSE American Company Guide. NYSE Regulation has reviewed the Company's compliance plan and has granted a plan period through September 24, 2019.

  • PR Newswire2 months ago

    BioPharmX Initiates Phase 2b Trial of BPX-04 for Rosacea

    MENLO PARK, Calif., Oct. 11, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today announced that it has enrolled the first subject in a Phase 2b clinical trial of BPX-04, a novel topical gel formulation of minocycline for the treatment of rosacea. The trial is a randomized, double-blind, vehicle-controlled study in subjects with inflammatory lesions of rosacea. The 12-week, multi-center study will evaluate BPX-04, a 1% topical minocycline, carried by the HyantX™ delivery system, a proprietary, anhydrous hydrophilic topical system developed by BioPharmX.  The trial plans to enroll 176 subjects at least 18 years old with an investigator's global assessment (IGA) score of 3 or 4 (moderate or severe), and 15 to 70 inflammatory lesions on their faces at baseline.

  • PR Newswire3 months ago

    BioPharmX Receives Notice of Noncompliance from NYSE American

    MENLO PARK, Calif., Sept. 28, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX) (the "Company"), a specialty pharmaceutical company developing products for the dermatology market, received a notice on September 24, 2018 from the NYSE American LLC (the "NYSE American") that the Company is not in compliance with the stockholders' equity requirements set forth in Sections 1003(a)(i)-(iii) of the NYSE American Company Guide. The Company reported stockholders' equity of $4.3 million as of July 31, 2018 and net losses in its five most recent fiscal years ended January 31, 2018.  The continued listing standards require listed companies to maintain stockholders' equity of $6.0 million or more if they have reported losses from continuing operations and/or net losses in their five most recent fiscal years (Section 1003(a)(iii)).

  • Who Are The Major Shareholders In BioPharmX Corporation (NYSEMKT:BPMX)?
    Simply Wall St.3 months ago

    Who Are The Major Shareholders In BioPharmX Corporation (NYSEMKT:BPMX)?

    The big shareholder groups in BioPharmX Corporation (NYSEMKT:BPMX) have power over the company. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies.Read More...

  • PR Newswire3 months ago

    BioPharmX Corporation Announces David S. Tierney, M.D. Joined the Company as Chief Executive Officer

    MENLO PARK, Calif., Sept. 12, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today announced the appointment of David S. Tierney, M.D., as its chief executive officer.  Anja Krammer continues to serve in her roles as president and corporate secretary for BioPharmX. Dr. Tierney was also appointed as a director to the board of directors of BioPharmX. BioPharmX Corporation noted that Dr. Tierney is an accomplished healthcare executive with a proven record of achievements leading the growth of both pharmaceutical and medical device companies.

  • ACCESSWIRE3 months ago

    Today’s Research Reports on Stocks to Watch: Agile Therapeutics and BioPharmX

    NEW YORK, NY / ACCESSWIRE / September 12, 2018 / It was a day of unexplainable gains for two biotech stocks on Tuesday. Both Agile Therapeutics and BioPharmX catapulted higher despite any significant news. ...

  • PR Newswire4 months ago

    BioPharmX Reports Second Quarter 2019 Financial Results

    MENLO PARK, Calif. , Aug. 30, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today reports financial ...

  • PR Newswire4 months ago

    BioPharmX Announces Results of Annual Shareholders Meeting

    MENLO PARK, Calif., Aug. 14, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today held its 2018 Annual Meeting of Shareholders (the "Annual Meeting"), and announced that each of BioPharmX's director nominees have been re-elected to the board of directors: Anja Krammer, Michael Hubbard and Stephen Morlock. BioPharmX Corporation (NYSE American: BPMX) is a Silicon Valley-based specialty pharmaceutical company, which seeks to provide products through proprietary platform technologies for prescription, over-the-counter (OTC), and supplement applications in the health and wellness markets, including dermatology and women's health.

  • PR Newswire4 months ago

    BioPharmX Announces Patent Award, Expanding Protection for Innovations in Solid Dosage Forms

    MENLO PARK, Calif., Aug. 9, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today announced that the U.S. Patent and Trademark Office has granted a fifth patent to the company – which means that three of its drug delivery systems now have patent protection. The patent, (U.S. Patent No. 10,034,899), entitled "Solid oral dosage form for breast symptoms," protects improvements in BioPharmX's novel system for the delivery of molecular iodine to treat fibrocystic breast condition. This is the third patent granted to BioPharmX this year.

  • PR Newswire5 months ago

    BioPharmX Receives IRB Approval to Initiate Phase 2 Trial of BPX-04 for the Treatment of Rosacea

    MENLO PARK, Calif., July 31, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today announced it has received Institutional Review Board approval for its phase 2 study of BPX-04 for the treatment of papulopustular rosacea. The company also announced that, based on data from its open-label feasibility study which assessed tolerability in subjects with papulopustular rosacea, it has selected the 1% minocycline concentration for use in the PRISM phase 2 trial to evaluate the safety and efficacy of BPX-04, continuing in its patient-centric commitment to antibiotic stewardship by utilizing a lower dose of antibiotics for patients.

  • ACCESSWIRE5 months ago

    Free Technical Insights on BioPharmX and Three Other Biotech Stocks

    LONDON, UK / ACCESSWIRE / July 26, 2018 / If you want a free Stock Review on BPMX sign up now at www.wallstequities.com/registration. WallStEquities.com shifts focus on the Biotechnology space, which consists of companies that are engaged in the research and development of new drugs, medical devices, and procedures. The industry includes the manufacturing and marketing of drugs as a result of direct research and development.

  • What Pushed BioPharmX Stock Up Yesterday?
    Market Realist5 months ago

    What Pushed BioPharmX Stock Up Yesterday?

    On July 19, specialty dermatology player BioPharmX (BPMX) announced that the FDA had waived the dermal carcinogenicity study it had required as part of the development program for BPX-01. BPX-01 is BioPharmX’s investigational topical minocycline gel for the treatment of patients suffering from inflammatory lesions due to acne vulgaris. The waiver implies that BioPharmX will save in terms of the time and resources that would have been required for the nonclinical research normally done for the FDA review.

  • ACCESSWIRE5 months ago

    Today’s Research Reports on Stocks to Watch: MiMedx Group and BiopharmX

    NEW YORK, NY / ACCESSWIRE / July 20, 2018 / MiMedx Group and BioPharmX both saw big jumps after announcing positive news. The former announced the appointment of a new Chief Compliance Officer while the latter announced that the Food and Drug Administration has waived its requirement for a dermal carcinogenicity study for BPX-01. Traders cheered at the news as this eliminates years of non-clinical research normally required for FDA review.

  • ACCESSWIRE5 months ago

    3 Biotech Stocks to Watch This Quarter

    CORAL GABLES, FL / ACCESSWIRE / July, 19 2018 / President Trump continues to put down the pharmaceutical industry on a regular basis, despite this biotech stocks are doing well over the last year. Since ...

  • PR Newswire5 months ago

    BioPharmX Announces FDA Grant of CARC Waiver and Post-Hoc Analysis for BPX-01

    MENLO PARK, Calif., July 19, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today announced that the U.S. Food and Drug Administration has waived its requirement for a dermal carcinogenicity study for BPX-01, eliminating several years of non-clinical research normally required for FDA review. BPX-01, a novel topical gel formulation of minocycline for the treatment of inflammatory acne, received the waiver based on the results of a 39-week dermal minipig toxicity study conducted by BioPharmX and the extensive safety history of minocycline products including the clinical safety data from the BPX-01 Phase 2 acne studies.

  • PR Newswire6 months ago

    New Patient-Centered Panel Helps BioPharmX Define its Role in the Future of Dermatology

    MENLO PARK, Calif., June 19, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing products for the dermatology market, has formed a Special Advisory Council of thought leaders from various disciplines to help the company embrace patient centricity in its products, pricing and market access considerations. The advisors, who bring decades of experience in fields beyond dermatology – ranging from regulatory pathways to market access and from infectious diseases to antibiotic resistance – will inform the company's efforts by providing the kind of strategic expertise needed to position BioPharmX as a leader in patient-centric dermatology.

  • ACCESSWIRE6 months ago

    Blog Exposure - bluebird bio Announces Encouraging New Data from Northstar (HGB-204) and Northstar-2 (HGB-207) Studies of LentiGlobin(TM) Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia

    LONDON, UK / ACCESSWIRE / June 19, 2018 / If you want access to our free research report on bluebird bio, Inc. (NASDAQ: BLUE), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=BLUE as the Company's latest news hit the wire. On June 15, 2018, the Company announced that it will present new data from the completed Phase-1/2 Northstar (HGB-204) study in adolescents and adults with transfusion-dependent β-thalassemia (TDT) and any genotype, and its ongoing, Phase-3 Northstar-2 (HGB-207) multicenter clinical study of LentiGlobin™ investigational gene therapy in patients with TDT and non-β0/β0 genotypes, at the 23rd Annual Congress of the European Hematology Association in Stockholm on June 16, 2018. Active-Investors.com is currently working on the research report for BioPharmX Corporation (NYSE: BPMX), which also belongs to the Healthcare sector as the Company bluebird bio.

  • ACCESSWIRE6 months ago

    Free Technical Research on BioPharmX and Three More Biotech Equities bio

    LONDON, UK / ACCESSWIRE / June 19, 2018/ If you want a free Stock Review on BPMX sign up now at www.wallstequities.com/registration. On Monday, June 18, 2018, the Dow Jones Industrial Average and the S&P 500 edged 0.41% and 0.21% lower, respectively at the closing bell, while the NASDAQ Composite stayed bullish, finishing marginally lower by 0.01%. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), BioPharmX Corp. (NYSE AMER: BPMX), BioTime Inc. (NYSE AMER: BTX), and bluebird bio Inc. (NASDAQ: BLUE).

  • PR Newswire6 months ago

    BioPharmX Reports First Quarter 2019 Financial Results

    MENLO PARK, Calif. , June 7, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today reports financial ...